Search Patents
  • CORONAVIRUS VACCINE
    Publication number: 20210322541
    Abstract: Provided herein is an isolated polynucleotide, which encodes alphavirus non-structural proteins nsp1, nsp2, nsp3 and nsp4 and a polypeptide comprising a coronavirus protein fused to a signal sequence and/or transmembrane domain. The coronavirus protein may be the receptor binding domain of the S1 subunit of coronavirus spike (S) protein. The polynucleotide such as RNA is useful for as a vaccine against coronavirus infection, especially, COVID-19 infection.
    Type: Application
    Filed: April 16, 2021
    Publication date: October 21, 2021
    Applicant: VLP Therapeutics, Inc.
    Inventors: Wataru AKAHATA, Jonathan F. SMITH, Ryuji UENO
  • ANTIBODY COCKTAIL AGAINST SARS-COV-2 SPIKE PROTEIN
    Publication number: 20220235118
    Abstract: Provided herein are antibodies that are useful for treating SARS-CoV-2 infections in a subject. Also provided herein are compositions comprising one or more antibodies, methods of treatment comprising administering one or more antibodies, and kits comprising one or more antibodies.
    Type: Application
    Filed: January 4, 2022
    Publication date: July 28, 2022
    Inventors: Matthew K. ROBINSON, Pavel NIKITIN, Michael John MORIN, Jillian DIMUZIO, Ray HOWANSKI, John P. DOWLING
  • Recombinant Spike Protein Subunit Based Vaccine for Porcine Epidemic Diarrhea Virus (PEDV)
    Publication number: 20150328307
    Abstract: The present invention encompasses porcine epidemic diarrhea virus (PEDV) vaccines or compositions. The vaccine or composition may be a vaccine or composition containing PEDV antigens. The invention also encompasses recombinant vectors encoding and expressing PEDV antigens, epitopes or immunogens which can be used to protect porcine animals against PEDV.
    Type: Application
    Filed: May 19, 2015
    Publication date: November 19, 2015
    Applicant: MERIAL, INC.
    Inventors: Paulraj Lawrence, Russell Bey
  • USE OF INTERFERENCE PEPTIDE IN PREPARATION OF ANTI-SARS-CoV-2 MEDICAMENT
    Publication number: 20220323537
    Abstract: An agent for inhibiting binding of transferrin receptor to SARS-CoV-2 spike protein or an anti-SARS-CoV-2 medicament is provided, where active pharmaceutical ingredients of the agent or the medicament include interference peptides, and the interference peptides include: SL8, FG8, DL12, RK4, SD6, HF7, and/or QK8.
    Type: Application
    Filed: June 22, 2020
    Publication date: October 13, 2022
    Inventors: Ren LAI, Xiaopeng TANG, Zhiyi LIAO
  • siRNA based on RNA sequence of SARS-CoV-2 and use thereof
    Publication number: 20230047473
    Abstract: The present disclosure provides siRNA that suppresses proliferation of new coronaviruses (SARS-CoV-2). The siRNA disclosed herein includes: a sense strand; and an antisense strand. The sense strand includes a target sequence comprising 19 to 23 bases in which a base at a 5? terminal is guanine (G) or cytosine (C), and an overhang comprising 2 to 4 bases added to a 3? terminal side of the target sequence. The antisense strand includes a sequence complementary to the target sequence, and an overhang comprising 2 to 4 bases added to a 3? terminal side of the complementary sequence. Here, at least a part of the target sequence contains at least a part of a base sequence encoding a signal peptide region of a spike protein (S protein) of SARS-CoV-2.
    Type: Application
    Filed: July 12, 2022
    Publication date: February 16, 2023
    Inventors: Tetsuhiko Yoshida, Nahoko Baileykobayashi, Kazuo Takayama, Rina Hashimoto, Yoshinori Yoshida
  • MESSENGER RNA VACCINES AGAINST WIDE SPECTRUM OF CORONAVIRUS VARIANTS
    Publication number: 20240066113
    Abstract: The present invention relates to the mRNA vaccine of coronavirus spike protein with deletion of glycosites in the receptor binding domain (RBD), the subunit 1 (S1) domain, or the subunit 2 (S2) domain, or a combination thereof. The vaccine elicits broadly protective immune responses coronavirus and variants thereof.
    Type: Application
    Filed: April 12, 2022
    Publication date: February 29, 2024
    Inventors: Chi-Huey WONG, Chung-Yi WU, Che MA, Chen-Yu FAN
  • NOVEL CORONAVIRUS ANTIBODY DETECTION KIT BASED ON MAGNETIC PARTICLE CHEMILUMINESCENCE
    Publication number: 20230296601
    Abstract: The present application provides a novel coronavirus antibody detection kit based on magnetic particle chemiluminescence. The detection kit includes: streptavidin magnetic particles, biotin-labeled novel coronavirus antigens, an acridine sulfonamide-labeled secondary antibody, a sample diluent and a quality control material; wherein the biotin-labeled novel coronavirus antigens include a recombinant nucleocapsid protein and a recombinant spike protein S1. The sample to be tested, the biotin-labeled antigens and the streptavidin magnetic particles are mixed, incubated and washed, and then the acridine sulfonamide-labeled antibody is added to form a magnetic particle-streptavidin-biotin-antigen-novel coronavirus antibody-secondary antibody complex, and then the luminous intensity is detected to qualitatively determine the sample to be tested.
    Type: Application
    Filed: March 24, 2021
    Publication date: September 21, 2023
    Inventors: Chunlong Liu, Zhou Zhang, Shaohua Ma, Jiashun Wang, Yan Su, Zeqi Zhou
  • MONOCLONAL ANTIBODY FOR SARS-CoV-2 SPIKE PROTEIN
    Publication number: 20220163529
    Abstract: An embodiment provides a method for detection of the COVID-19 virus, including: obtaining a body fluid from a patient; exposing the body fluid to at least one binding antibody, wherein the at least one binding antibody binds to an antigen in the body fluid; forming an antigen antibody complex; and determining the presence of the antigen antibody complex. Other aspects are described and claimed.
    Type: Application
    Filed: November 17, 2021
    Publication date: May 26, 2022
    Inventors: Qiang Chen, Mitchell Steven Felder
  • Compositions and methods for diagnosing and preventing severe acute respiratory syndrome (SARS)
    Publication number: 20050112559
    Abstract: The present invention relates to the fields of immunology and molecular biology and describes compositions and methods for using proteins, peptides and nucleic acids related to the SARS CoV nucleocapsid protein and the spike glycoprotein. In particular, the present invention provides immunostimulatory preparations, prophylactic pharmaceutical preparations, diagnostic assays and kits for identifying and preventing SARS infections.
    Type: Application
    Filed: September 29, 2004
    Publication date: May 26, 2005
    Inventors: Tze Ming Leung, Chi Hang Tam, Chun Ma, Pak Lim, Kay Sheung Chan
  • ORGANOSILICON CARRIERS FOR USE IN TREATING INFECTIONS AND/OR DISEASES CAUSED BY SARS VIRUSES
    Publication number: 20210346305
    Abstract: A method for treating, attenuating or inhibiting an infection and/or disease associated with a SARS virus in a subject is provided that includes administering a pharmaceutical composition to the subject. The composition includes an organosilicone carrier with one or more active substances that block and/or inhibit an ACE2 receptor in a host cell of the subject, the spike protein of a SARS virus and/or internal components of a virion of the SARS virus.
    Type: Application
    Filed: May 11, 2020
    Publication date: November 11, 2021
    Inventor: Zoser B. Salama
  • NEUTRALIZING VACCINES AGAINST HUMAN CORONAVIRUS
    Publication number: 20220160822
    Abstract: The present invention provides both QuilA-loaded chitosan (QAC)-encapsulated DNA vaccine compositions and viral vaccine compositions that encode a SARs-CoV-2 spike (S) protein, a SARs-CoV-2 nucleocapsid (N) protein, or both the S protein and the N protein. Additionally, the present invention provides methods in which the disclosed vaccines are administered to a subject to induce an immune response against SARS-CoV-2.
    Type: Application
    Filed: November 23, 2021
    Publication date: May 26, 2022
    Inventors: Adel M. Talaat, Shaswath Chandrasekar
  • IMPROVED DNA VACCINE FOR SARS-COV-2
    Publication number: 20230330214
    Abstract: Provided is DNA that: encodes a coronavirus (SARS CoV-2) spike protein or a fragment thereof; and has been optimized to partially or fully exhibit a codon included in a DNA sequence.
    Type: Application
    Filed: September 30, 2021
    Publication date: October 19, 2023
    Applicants: OSAKA UNIVERSITY, TAKARA BIO INC., ANGES, INC.
    Inventors: Hironori NAKAGAMI, Ryuichi MORISHITA, Hiroki HAYASHI, Yasunori AMAISHI, Sachiko OKAMOTO, Junichi MINENO, Hisato IKAI, Junko MICHIBATA, Takao KOMATSUNO
  • ANTIBODY COCKTAIL AGAINST SARS-COV-2 SPIKE PROTEIN
    Publication number: 20240067704
    Abstract: Provided herein are antibodies that are useful for treating SARS-CoV-2 infections in a subject. Also provided herein are compositions comprising one or more antibodies, methods of treatment comprising administering one or more antibodies, and kits comprising one or more antibodies.
    Type: Application
    Filed: October 24, 2023
    Publication date: February 29, 2024
    Inventors: Matthew K. ROBINSON, Pavel NIKITIN, Michael John MORIN, Jillian DIMUZIO, Ray HOWANSKI, John P. DOWLING
  • IMMUNOGENIC COMPOSITION FORMING A VACCINE, AND A METHOD FOR ITS MANUFACTURE
    Publication number: 20210299251
    Abstract: An immunogenic composition forming a vaccine includes a nanoparticle adjuvant comprising at least a nanoparticle, wherein the at least a nanoparticle comprises a lipid layer exterior including a plurality of lipids, cholesterol, and a primary alkyl amine including a positively charged amino group head and at least a carbon tail and an antigen incorporated in the at least a nanoparticle, wherein the antigen comprises a spike protein from a coronavirus.
    Type: Application
    Filed: July 10, 2020
    Publication date: September 30, 2021
    Inventors: Mitra Mosharraf, Aryo Sorayya, Rajiv Nayar
  • USE OF SARS-CoV-2 RECEPTOR BINDING MOTIF (RBM)-REACTIVE MONOCLONAL ANTIBODIES TO TREAT COVID-19
    Publication number: 20230287090
    Abstract: Provided SARS-CoV-2 receptor binding motif (RBM)-reactive monoclonal antibodies and fragments thereof, which inhibit the interaction between the spike protein RBM and human ACE2, as well as methods of use employing such antibodies and/or fragments.
    Type: Application
    Filed: August 30, 2021
    Publication date: September 14, 2023
    Inventors: Haichao WANG, Kevin J. TRACEY, Jian Hua LI, Cassie ZHU, Xiaoling QIANG
  • SARS-COV-2 THERAPIES
    Publication number: 20230348597
    Abstract: Disclosed are bispecific molecules combining ACE2 with an anti-CD3 antibody and engineered T cells expressing chimeric antigen receptors that bind to SARS-CoV-2 spike protein, as well as related compositions and methods. The methods and compositions provided can be used for treating early-stage and/or late-stage SARS-CoV-2 infections, independent of the SARS-CoV-2 variant.
    Type: Application
    Filed: March 13, 2023
    Publication date: November 2, 2023
    Applicant: The Jackson Laboratory
    Inventors: Mikail Dogan, Derya Unutmaz
  • ANTIVIRAL PEPTIDES FOR TREATMENT OF THE MIDDLE EAST RESPIRATORY SYNDROME
    Publication number: 20200306338
    Abstract: A peptide that binds to the Si spike protein of Middle East Respiratory syndrome coronavirus or MERS-CoV and a method for inhibiting infection of a subject exposed to or having MERS-CoV by administering the peptide.
    Type: Application
    Filed: March 26, 2020
    Publication date: October 1, 2020
    Applicants: National Guard Health Affairs, King Saud bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center
    Inventors: Musa Nur GABERE, Sabeena MUSTAFA, Hanan BALKHY, Mohamed HUSSEIN, Ibraheem Abdulaziz BUSHNAK
  • A NOVEL SARS IMMUNOGENIC COMPOSITION
    Publication number: 20160376321
    Abstract: Embodiments of the disclosure concern immunogenic compositions and methods for treating or preventing Severe acute respiratory syndrome (SARS). The compositions and methods concern a portion of the receptor-binding domain (RBD) of the SARS-CoV spike protein. In at least particular cases, a mutated version of a portion of the RBD is utilized, such as a deglycosylated mutant of the RBD.
    Type: Application
    Filed: November 21, 2014
    Publication date: December 29, 2016
    Applicant: BAYLOR COLLEGE OF MEDICINE
    Inventors: Peter Jay Hotez, Maria Elena Bottazzi, Bin Zhan, Wen-Hsiang Chen, Shivali Chag
  • SARS COV-2 SPIKE PROTEIN CONSTRUCT
    Publication number: 20230364219
    Abstract: Compounds useful as components of immunogenic compositions for the induction of an immunogenic response in a subject against infection, methods for their use in treatment, and processes for their manufacture are provided herein. The compounds comprise a nucleic acid construct comprising a sequence which encodes an antigen, in particular a Coronavirus antigen.
    Type: Application
    Filed: April 16, 2021
    Publication date: November 16, 2023
    Applicant: GlaxoSmithKline Biologicals SA
    Inventors: Dong YU, Giulietta MARUGGI, Jason W. WESTERBECK, Jeffrey B. ULMER, Jason P. LALIBERTE, Kate LUISI, Lin QU
  • ADJUVANTED SUBCUTANEOUSLY-ADMINISTERED POLYPEPTIDE SARS-COV-2 VACCINES COMPOSITION AND METHODS
    Publication number: 20240131139
    Abstract: Disclosed herein are subcutaneously administered, immunogenic compositions (e.g., vaccines) and methods of using and preparing the same. In some embodiments, the immunogenic compositions generate IgG antibodies to the spike proteins of the Wuhan-Hu-1, Delta B.1.617.2, and Omicron BA.1 variants of SARS-CoV-2 and may be suitable for use in preventing an infectious disease, such as SARS-CoV-2.
    Type: Application
    Filed: November 9, 2022
    Publication date: April 25, 2024
    Inventors: Michael Bowe, David Craig Wright
Narrow Results

Filter by US Classification